The global sales of high flow ventilators are estimated to be worth USD 1.99 billion in 2024 and anticipated to reach a value of USD 3.77 billion by 2034. Sales are projected to rise at a CAGR of 6.6% over the forecast period between 2024 and 2034. The revenue generated by high flow ventilators in 2023 was USD 1.87 billion.
Chronic respiratory conditions like chronic obstructive pulmonary disease (COPD), asthma, and acute respiratory distress syndrome (ARDS) have become increasingly common worldwide, impacting billions of lives and creating a heightened demand for effective respiratory support solutions.
This surge in respiratory illnesses, compounded by the global threat of infectious diseases such as influenza and COVID-19, has led to a greater reliance on high flow ventilators (HFNCs) for managing these conditions.
Global High Flow Ventilators Industry Assessment
| Attributes | Key Insights |
|---|---|
| Historical Size, 2023 | USD 1.87 billion |
| Estimated Size, 2024 | USD 1.99 billion |
| Projected Size, 2034 | USD 3.77 billion |
| Value-based CAGR (2024 to 2034) | 6.6% |
In 2019, Goldberg's occupational lung disease (GOLD) estimated the rate of chronic obstructive pulmonary disease (COPD) worldwide was 10.3% with a total of about 391.9 billion cases in those aged 30 to 79 years. This international data illustrates the heavy toll of COPD worldwide and identifies effective management and intervention strategies required to deal with this burgeoning health problem.
Rising chronic obstructive pulmonary disease (COPD) cases and complex respiratory diseases worldwide affecting airflow limitation among individuals. COPD is now the third leading cause of mortality worldwide, after heart disease and stroke.
Ultimately, conjunction of airway collapse with sudden hypoxemia results in acute exacerbations of COPD which demand prompt ventilator support. Thus, high-flow ventilators are critical in such scenarios due to the high-flow oxygen therapy, which, besides alleviating symptoms, also avoids invasive ventilation methods.
Seasonal influenza incidences leading to severe respiratory illness among billions worldwide. These usually happen to high-risk immune-compromised patients who are already at risk of infection leading to a significant demand on respiratory support and hospitalization.
Particularly in these situations, high-flow ventilators are very useful, providing a less-invasive way to give these patients high-flow oxygen to help them recover without the need for intubation.
The below table presents the expected CAGR for the global high flow ventilators market over several semi-annual periods spanning from 2024 to 2034. In the first half (H1) of the decade from 2023 to 2033, the business is predicted to surge at a CAGR of 7.3%, followed by a slightly lower growth rate of 7.0% in the second half (H2) of the same decade.
| Particular | Value CAGR |
|---|---|
| H1 | 7.3% (2023 to 2033) |
| H2 | 7.0% (2023 to 2033) |
| H1 | 6.6% (2024 to 2034) |
| H2 | 6.1% (2024 to 2034) |
The above table presents the expected CAGR for the global high flow ventilators market over several semi-annual periods spanning from 2024 to 2034. In the first half (H1) of the decade from 2023 to 2033, the business is predicted to surge at a CAGR of 7.3%, followed by a slightly decline in growth rate of 7.0% in the second half (H2) of the same decade.
Moving into the subsequent period, from H1 2024 to H2 2034, the CAGR is projected to decrease slightly to 6.6% in the first half and increase moderately at 6.1% in the second half. In the first half (H1) the market witnessed a decrease of 70.00 BPS while in the second half (H2), the market witnessed an decrease of 90.00 BPS.
Physiological Benefits of High Flow Therapy Play a Crucial Role as A Driver for The High Flow Ventilators Market
Latest revolutions in respiratory care is high flow therapy which has recently emerged, especially among patients with a compromise in the respiratory function. This therapy involves heated and humidified oxygen being delivered in large volumes, usually between 30 to 60 liters per minute, via nasal cannulas.
The physiological benefits are huge with regard to high flow therapy, especially in washing out carbon dioxide from the upper airways and reducing the work of breathing, which together enhance ventilation efficiency and improve gas exchange in the lungs.
In patients with respiratory distress, where conditions such as chronic obstructive pulmonary disease or acute respiratory failure may lead to the accumulation of CO2 within the upper airways as a result of poor ventilation.
High flow therapy excludes out this dead space with gas enriched with oxygen, thus greatly enhancing the efficiency of ventilation. It also serves to stabilize arterial CO2 levels, thereby playing an important role in avoiding respiratory acidosis.
High-flow nasal cannula therapy, when compared to other modes of oxygen therapy or NIV, has demonstrated a decreased requirement for intubation in acute respiratory failure patients. This noninvasive technique thus presents a safer option in the management of respiratory distress while decreasing complications associated with the use of invasive techniques.
High-flow therapy addresses some very important needs: the effectiveness of ventilation, gas exchange, and patient comfort in managing respiratory distress for a wide array of patient populations.
The Positive Impact of COVID-19 has Driven the Growth of High Flow Ventilators Sales
While COVID-19 evolved into a pandemic, it soon became obvious that a large percentage of the infected population developed acute hypoxemic respiratory failure. Such conditions did call for appropriate respiratory support, maintaining a good level of oxygenation to avoid further deterioration.
High Flow Nasal Oxygen (HFNO) rapidly became one of the first treatments of choice in patients with mild to moderate respiratory distress. Research has shown that HFNO significantly improves oxygenation and reduces the need for invasive mechanical ventilation, which is critical to managing surges in COVID-19 cases.
High flow therapy is important in improving comfort for a patient through the delivery of high flow rates of heated and humidified air. COVID-19 patients receiving HFNO reported less discomfort as compared to traditional oxygen delivery methods that normally involve nasal cannulas or face masks, which are known to cause irritation from prolonged use.
Regulatory agencies expedited the approval of new devices, thereby making equipment more available to healthcare providers. In such an environment, engineers and healthcare professionals started working together, developing these emergency respiratory support devices for specific needs in COVID-19 patients.
In conclusion, apart from the increase in production, there was a surge in investment into research and development regarding high flow ventilators. Companies saw the long-term potential of these devices not only in the management of COVID-19 but also in chronic respiratory conditions such as COPD and asthma.
The Emphasis on Improved Patient Comfort Is a Significant Driver for The High Flow Ventilators Market
The prominent advantage of high flow ventilators compared to other modes of oxygen delivery through conventional face mask and invasive mechanical ventilation contribute to their increased acceptance among healthcare professionals and patients.
With this, the focus on patient comfort associated with the use of HFNCs is driving its adoption across several healthcare environments including hospitals, long-term care, and even home care environments.
The discomfort associated with traditional methods of oxygen delivery, like face masks and NIV devices, including CPAP machines, is due to the generally restrictive and clumsy design. Face masks may be claustrophobic to the patient, impede communication, and make eating and drinking difficult or impossible.
Although effective for a selected group of patients in specific situations, NIV devices result in pressure sores, nasal dryness, and gastric distension. Consequently, poor tolerance to these techniques leads to poor compliance.
High flow ventilators administer high-flow oxygen through softer nasal prongs, which should be more comfortable to wear and much less invasive. This less-restrictive setup allows for greater mobility, talking, and eating without as much encumbrance, which results in higher patient satisfaction and better therapy adherence.
Improved compliance with respiratory care is directly related to the efficacy of treatment and overall outcomes of treatment. Thus, HFNCs improve comfort and decrease the physical and psychical burden of respiratory support; this contributes to better management of respiratory distress and lesser need for escalation to the more invasive ventilation modalities.
The Complexity of HFNC Therapy Acts as a Barrier to the Broader Adoption of High Flow Ventilators
HFNC systems are significantly more complex compared with conventional methods of oxygen delivery, and their safe and effective application requires adequate knowledge in respiratory physiology, technology, and patient management. The focus on enhancing patient comfort is driving the adoption of HFNCs across various healthcare settings, including hospitals, long-term care facilities, and even home care environments.
Traditional oxygen delivery methods, such as face masks and non-invasive ventilation (NIV) devices like continuous positive airway pressure (CPAP) machines, usually cause discomfort due to their restrictive and often complex design.
Patients on HFNC need constant care to observe changes in respiratory status. This includes observation of the patient's vital signs: respiratory rate, oxygen saturation, and signs of respiratory fatigue. Each one of these parameters requires a certain amount of interpretation and timely adjustment; hence, it demands a specific knowledge base related to respiratory care.
The inherent complexity of HFNC therapy itself might discourage health facilities from embracing high-flow ventilators, at least for less specialized training of the staff. Without being able to provide clinicians who can skillfully operate HFNC systems, some facilities may view the investment in these systems as a constraint to market penetration.
The global high flow ventilators industry recorded a CAGR of 5.3% during the historical period between 2019 and 2023. The growth of high flow ventilators industry was positive as it reached a value of USD 1.87 billion in 2023 from USD 1.44 billion in 2019.
The initial methods of ventilation involved basic mechanical devices that used positive pressure to assist breathing. Among the earliest devices was the iron lung, which utilized negative pressure to aid respiration, primarily for polio patients.
These early devices were large and cumbersome, and their operation was complex. As technology advanced, more sophisticated invasive mechanical ventilators were developed. These devices allowed for precise control over ventilation parameters and were primarily used in intensive care units (ICUs).
Non-invasive ventilation modes, such as continuous positive airway pressure and Bi-Level positive airway pressure, marked the beginning of less invasive treatments. These ventilators allowed for respiratory support of the patient without the use of intubation; thus, increasing patient comfort and minimizing complications.
High-flow nasal cannula technology is one of the more recent innovations, which generally refers to high flow rates of heated and humidified oxygen administered through nasal prongs. HFNC provides effective respiratory support with minimal invasion.
Applications of high-flow ventilators are expected to increase beyond critical care to greater uses in emergency care, home care, and in long-term management settings for chronic respiratory conditions. Such growth will be based on increasing demand for flexible, effective, and non-invasive respiratory support.
Tier 1 companies comprise market leaders with a market revenue of above USD 100 billion capturing significant market share of 61.5% in global market. These companies are industry leaders with advanced technological capabilities, extensive research and development efforts, and strong financial resources.
Robust distribution networks and strategic partnerships with healthcare providers and technology firms go on to strengthen this leading market position. Prominent companies in tier 1 include Getinge AB, Medtronic PLC and Koninklijke Philips NV.
Tier 2 companies include mid-size players with revenue of USD 50 to 100 billion having presence in specific regions and highly influencing the local market and holds around 25.7% market share. The high flow ventilators market is contributed to by tier 2 companies that have growing influence in the market. Most of the companies are focused on specific niche areas within the area of ventilators.
A significant number of tier 2 companies focus on cost-effective solutions and strategic collaborations that increase their market reach. They invest in developing advanced devices and enhancing patient experience with the prime target of capturing segments of the market. Prominent companies in tier 2 include HERSILL, Hamilton Medical, ResMed and VYAIRE.
Finally, Tier 3 companies, such as ZOLL Medical Corporation, Essex Industries, Inc. and Tecno-Gaz S.p.A. They specialize in specific products and cater to niche markets, adding diversity to the industry.
The section below covers the industry analysis for the high flow ventilators market for different countries. Market demand analysis on key countries in several regions of the globe, including North America, Asia Pacific, Europe, and others, is provided. The United States is anticipated to remain at the forefront in North America, with higher market share through 2034. In Asia Pacific, India is projected to witness a CAGR of 7.7% by 2034.
| Countries | Value CAGR (2024 to 2034) |
|---|---|
| China | 6.8% |
| India | 7.7% |
| USA | 2.1% |
| South Korea | 5.4% |
| Canada | 3.7% |
| Spain | 3.9% |
| Germany | 2.1% |
| France | 3.5% |
USA high flow ventilators market is poised to exhibit a CAGR of 2.1% between 2024 and 2034. Currently, it holds the highest share in the North America market, and the trend is expected to continue during the forecast period.
The USA market is driven by the advanced technology coupled with high consumer demand. One of the major reasons for this dominance is the leading role that the country plays in applying innovative technologies to medical science.
Companies based in the USA represent some of the innovators when it comes to designing and developing highly sophisticated kinds of high flow ventilators, characterized by accurate regulation of respiratory supports and integrated with cutting-edge features like automatic settings, real-time monitoring, and increased comfort for patients.
Apart from technological advancement, high demand from consumers in the USA is also a driver for market growth. The USA health system focuses on quality care and advanced solutions, which influences hospitals and healthcare facilities to search for the latest technologies in high flow ventilators.
China high flow ventilators market is poised to exhibit a CAGR of 6.8% between 2024 and 2034. Currently, it holds the highest share in the East Asian market, and the trend is expected to continue during the forecast period.
The Chinese tech companies have been at the leading edge of designing high flow ventilators among other advanced medical technologies. Thus, their innovative nature spawns into the development of sophisticated and efficient devices that meet the increased demands for advanced respiratory care. In addition, it improves the functionality and reliability of the high flow ventilators, thereby increasing their appeal to health caregivers.
The manufacturing lines in China have given technology companies the unprecedented manufacturing capability to build such high-flow ventilators at low costs.
Cost advantages in production and supply management in the country drive down the cost of such devices, hence their increased accessibility in the region. Growth by technology companies leads to expanded distribution networks and after-sales services to facilitate wider market access within East Asia.
India’s high flow ventilators market is poised to exhibit a CAGR of 7.7% between 2024 and 2034. Currently, it holds the highest share in the Asia Pacific market, and the trend is expected to continue during the forecast period.
India is continuously investing in its health infrastructure by expanding and upgrading it. Initiatives by the government to ensure easier access to and higher quality of care, among other programs like the National Health Mission and Ayushman Bharat, have increased the capacity of hospitals and health facilities.
As infrastructure expands, so does the need for more sophisticated medical technologies that support improved respiratory care; examples include high-flow ventilators.
India offers opportunities for local manufacturing and partnerships with international companies. The government's support for the “Make in India” initiative provides incentives for domestic production, reducing costs and improving accessibility to high flow ventilators.
The section contains information about the leading segments in the industry. By modality, the trolley mounted high flow ventilators segment holds the highest market share of 76.5% in 2024.
| By Modality | Trolley mounted high flow ventilators |
|---|---|
| Value Share (2024) | 76.5% |
Trolley mounted high flow ventilators dominated the modality segment in the high flow ventilators market due to its versatility, mobility, and all-inclusive features. These ventilators are designed to deliver high flow oxygen therapy in a variety of clinical settings, starting from ICUs to emergency departments, hence, are an essential tool in the management of patients in acute respiratory distress.
Designed to be trolley-mounted, it is easy to maneuver through the hospital setting and hence quickly relocate the ventilator to where it is needed most in any urgent or transfer situation.
This makes them really important in a fast-moving health environment, as it allows practitioners to give timely respiratory support without being hampered by a fixed installation. The flexibility of the ventilators extends the areas of application, which includes recovery after surgery, emergency situations, and extended ventilation.
| By End User | Hospitals |
|---|---|
| Value Share (2024) | 38.4% |
Critical respiratory conditions that need immediate and highly intensive interventions can be managed in a hospital setup. Hospitals are prominent in management of patients with acute respiratory distress, COPD, asthma, pneumonia, and other life-threatening states.
These ventilators provide non-invasive respiratory support through high concentrations of oxygen for the stabilization of patients, especially when conventional oxygen therapy has proved to be inadequate. Therefore, the ability of hospitals to provide high-level care makes them the foremost setting for the deployment of high flow ventilators.
The management of heavy respiratory emergencies during the COVID-19 pandemic highlighted the importance of hospitals. Increased sudden patients suffering from severe respiratory distress made the demand for high flow ventilators in hospitals a necessity.
High-flow ventilators were an essential treatment modality in managing COVID-19 patients with moderate to severe manifestations and an important alternative to invasive mechanical ventilation that would help alleviate the strain on the intensive care unit.
The market players are imperatively employing strategic ways to compete and capture business shares, increasing product differentiation through new product launches and strategic acquisitions, and looking for strategic partners who can support them in widening their product portfolios for global market reach.
Recent Industry Developments in High Flow Ventilators Market
In terms of modality, the industry is divided into portable high flow ventilators and trolley mounted high flow ventilators.
In the terms of end user, the market is segmented into hospitals, ambulatory surgical centers, specialty clinics, long term care centers and others.
Key countries of North America, Latin America, Western Europe, Eastern Europe, South Asia & Pacific, East Asia and Middle East and Africa (MEA) have been covered in the report.
The global high flow ventilators market is projected to witness CAGR of 6.6% between 2024 and 2034.
The global high flow ventilators industry stood at USD 1.87 billion in 2023.
The global high flow ventilators market is anticipated to reach USD 3.77 billion by 2034 end.
India is set to record the highest CAGR of 7.7% in the assessment period.
The key players operating in the global high flow ventilators market include Getinge AB, Hamilton Medical, HERSILL, Koninklijke Philips NV, Medtronic PLC, ResMed, VYAIRE, ZOLL Medical Corporation, Essex Industries, Inc. and Tecno-Gaz S.p.A.
Explore Similar Insights
High Flow Ventilators Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
